🔍
C03416: HIF-1aDP, A Constitutively-Expressed form of Hypoxia-Inducible Factor 1a
Case ID:
C03416
Report of Invention:
5/1/1998
Web Published:
3/24/2015
C03416: HIF-1aDP, A Constitutively-Expressed form of Hypoxia-Inducible Factor 1a
Technical Details:
It has previously been demonstrated that a truncation of HIF-1alpha after amino acid residue 390 results in a constitutively expressed form of the protein. The purpose of this work was to identify mechanisms by which the half-life of the HIF1alpha protein is modulated as a function of cellular O2 concentration, such that the stability of the protein is greater under hypoxic, relative to non-hypoxic conditions. The strategy employed was to introduce mutations into the protein-coding DNA sequence and to identify mutants, which no longer manifested decreased protein stability under non-hypoxic conditions. This strategy was designed to (1) identify important regions of regulation with the HIF-1alpha molecule; and (2) engineer a constitutively stable form of HIF-1alpha that could be utilized for gene therapy of ischemic cardiovascular disease.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://jhu.technologypublisher.com/technology/18718
Inventors:
Category(s):
Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Christine Joseph
cjoseph6@jhmi.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum